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Aim: To develop and pilot an algorithm to select older people for different types of
medication review based on their case complexity.
Methods: Experts rated complexity of patient cases through a Delphi-consensus
method. The case characteristics were included in a regression model predicting
complexity to develop a criteria-based algorithm. The algorithm was piloted in four
community pharmacies with 38 patients of high and low complexity. Pharmacists
conducted medication reviews according to their personal judgment and rated the
patients’ complexity. Time needed for reviewing and number of interventions (proposed
and implemented) were assessed. Feasibility was evaluated with in-depth interviews.
Results: We developed the algorithmwith 75 cases proceeding from patients in average
79 years old and using 10 prescribed medications. The regression model (adjusted
R2 = 0.726, P < 0.0001) resulted in the following criteria for the algorithm: “number
of medications”×1 + “number of prescribers”×3 + “recent fall incident”×7 + “does not
collect own medication”×4. The pharmacists performed advanced medication reviews
with all patients. The time needed to perform the medication review did not differ
significantly according to case complexity (76.9min for high complexity; 66.1min for
low complexity). Agreement between the algorithm scores and the pharmacists’ ratings
on complexity degree was slight to moderate (Kappa 0.16–0.42). The pharmacists had
mixed opinions about the feasibility of applying the algorithm, particularly regarding the
criterion “fall incidents.”
Conclusion: We developed an algorithm with four criteria that distinguished between
high and low complexity patients as rated by experts. Additional validation steps are
needed before implementation.
Keywords: medication reviews, polypharmacy, patient selection, aged, primary care
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INTRODUCTION
Aging and polypharmacy are associated with an increased risk
of medication-related harm (Leendertse et al., 2008; Kaufmann
et al., 2015). Medication reviews have shown to reduce the
number of inappropriately used medications and resultant drug-
related problems (Holland et al., 2008). Medication reviews have
been implemented in many countries (Bulajeva et al., 2014),
although effects on outcomes like hospital admissions or quality
of life have not been consistently demonstrated (Holland et al.,
2005, 2008; Lenaghan et al., 2007; Hatah et al., 2014; Huiskes
et al., 2017; Hurmuz et al., 2018). Three types of medication
reviews have been put forward (Blenkinsopp et al., 2012; Griese-
Mammen et al., 2018). These are simple reviews based on the
pharmacy medication history only, intermediate reviews for
which the patient provides additional information and advanced
reviews that make use of more extensive clinical information.
Currently there are no uniform or evidence-based strategies
to select patients for different types of medication reviews.
Commonly used criteria to select patients for medication reviews
include an age of 65 years or older and the chronic use of multiple
medications (Huiskes et al., 2017). In the Netherlands, advanced
clinical medication reviews are recommended for all older
patients with a high case complexity (Nederlands Huisartsen
Genootschap, 2012). Case complexity refers to the patient’s
overall status, including polypharmacy, multimorbidity, and
psycho-social problems (Huyse et al., 2007). The Dutch guideline
states that patients should be selected for an advancedmedication
review if they are ≥65 years of age, take ≥5 chronic medications
and have at least one additional risk factor. These risk
factors include having a reduced kidney function, a diminished
cognition, an increased fall risk, low medication adherence,
an unplanned hospitalization in the past year, or living in
a nursing home.
Selection of patients according to the Dutch guideline
recommendations turned out to be not feasible in practice.
Information regarding the additional risk factors is not
routinely available to the community pharmacists. Without this
information large numbers of patients were selected, though
not all needed an advanced medication review (Pharmaceutisch
Weekblad, 2015). The laborious nature of advanced reviews
unnecessarily burdens healthcare professionals. Therefore,
the Dutch Healthcare Inspectorate decided that advanced
medication reviews should at least be conducted for all patients
of≥75 years of age, with≥7 chronic medications and a decreased
kidney function (Landelijke Huisartsen Vereniging, 2016;
Pharmaceutisch Weekblad, 2016). This pragmatic approach
received criticism because it would lead to the exclusion of a
large group of older patients for whom a medication review
could be beneficial. A new approach with different criteria is
needed that allows patients to be allocated to different types of
medication reviews.
The aim of our study is firstly to develop a criteria-based
algorithm for the allocation of older people (≥65 years and
with ≥5 medications) for simple or advanced medication
reviews, based on their case complexity. Secondly, we piloted the
algorithm in the community pharmacy setting.
METHODS
Algorithm Development
We used judgment analysis to derive the criteria predicting case
complexity to be included in the algorithm (Cooksey, 1996).
Two panels of experts provided patient cases and rated their
complexity. Panel A consisted of four community pharmacists
and four general practitioners (GPs) and panel B consisted of five
community pharmacists and three GPs.
Patient Cases
The experts were asked to submit four to six cases of patients
using at least five chronic medications with varying complexity.
High complexity was defined as a case for which existing
treatment guidelines cannot be easily applied and an advanced
medication review is required to optimize treatment. Low
complexity was defined as a case for which existing treatment
guidelines can be applied as part of a simple medication review in
order to optimize treatment. The experts completed a structured
case report form with case characteristics (Appendix I). This
consisted of the patient’s medication, morbidity, laboratory
measurements, demographics, estimated medication use issues,
estimated beliefs about medication and other possible risk factors
for drug-related problems such as diminished cognition. The goal
was to obtain 80 cases; using the rule of 10 subjects per predictor,
this would be sufficient to develop an algorithmwith eight criteria
using regression modeling (Morgan et al., 2007). To achieve this
number, we used all cases provided by the experts and generated
additional cases. We modified a number of characteristics
from a subset of randomly selected experts’ cases. Level of
education, eyesight, age, sex, and medication intake issues were
systematically changed. Also, we exchanged one health issue and
its corresponding medication with another health issue and its
corresponding medication. All additional cases were checked by
two researchers to ensure they remained realistic.
Expert Ratings
All cases were rated by the two expert panels using a modified
Delphi method. For this, each panel rated the complexity of
cases provided by the opposite panel on a 9-point Likert scale
(1 = low complexity 9 = high complexity). Consensus per case
was calculated according to the Interpercentile Range Adjusted
for Symmetry method (Fitch et al., 2001). This method corrects
for outliers by using the range between the 0.3 and the 0.7
percentile instead of the full range. A correction factor is used
to adjust for symmetry of the ratings. Cases for which there was
no consensus were discussed in a consensus meeting. A case
was presented, the experts explained and discussed why they had
given a specific rating of complexity, and after the discussion
the experts were asked whether they wanted to reconsider their
rating. For each case, the median of the individual complexity
ratings of the experts was calculated.
Building the Algorithm
The algorithm was built using all cases for which consensus had
been reached. The median complexity rating was used as the
outcome in linear regression models, where potential criteria
were included as predictors. A wide range of clinical, medication
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and patient characteristics were included in the models, some
of which could be proxies for criteria that may be difficult to
measure. In total 48 potential criteria in 25 categories were tested
as predictors (Appendix II). Predictors were clustered when
they were derived from the same information or represented
a similar concept. A complete case linear regression procedure
was followed, with only one predictor from the same cluster
included so as to avoid collinearity. Predictors with a P-value
of 0.25 or less in the univariate testing were included in the
multivariate regression model. Per cluster the predictor with
the lowest P-value in univariate testing was included in the
first model. Predictors were excluded from the model until
excluding another predictor would reduce the adjusted R2 by
≥0.05. When a predictor was removed from the model during
the backward stepwise process, alternative predictor(s) from
the same cluster were tested. The weights of the predictors
of the final regression model were multiplied by 1
Lowest weight
and rounded to the nearest whole number. The final algorithm
consisted of the weighted predictors (criteria). With this the
algorithm scores were calculated where a higher score indicated
higher complexity.
Pilot Study
The algorithm was piloted in four community pharmacies. The
algorithm scores were compared with complexity ratings of the
pharmacists as well as experts. The feasibility of applying the
algorithm in practice was assessed with in-depth interviews with
the participating pharmacists. The medication review process
was evaluated.
Setting
The four participating community pharmacies, located in the
northern part of the Netherlands, offer standard pharmaceutical
care, including the monitoring of drug-drug interactions, contra-
indications, along with dose control, and patient counseling.
Furthermore, they have implemented advanced medication
reviews in accordance with the Dutch guideline (van der Meer
et al., 2015). All pharmacists routinely collaborate with the GPs
including regular pharmacotherapy audit meetings.
Patient Selection and Medication Review
Patients for whom a medication review is reimbursed in the
Netherlands were eligible for the pilot study. Thus, eligibility
was defined as ≥65 years, ≥5 chronic prescriptions and not
having received a medication review in the previous 12 months.
The pharmacists invited a random sample of 100 patients
per pharmacy to participate. Informed consent was collected
from patients who accepted to participate. Consenting patients
completed a questionnaire either by mail or by phone to
collect the additional information needed for the algorithm,
that is whether they collect their own medication, the number
of prescribers and whether they experienced a fall recently
(Appendix III). For each patient, the number of used medication
was calculated including all prescriptions for medication
at the lowest level ATC code, excluding non-therapeutic
ophthalmologicals (S01K, S01J, S02DC), caries prophylactic
agents (A01AA), over-the-counter vitamins (belonging to A11),
blood substitutes and perfusion solutions (B05), emollients,
protective, and other dermatologicals (D02, D11) (ATC/DDD
Index, 2018). After applying the algorithm to all respondents we
randomly selected five from the highest tertile and five from the
lowest tertile of the algorithm scores for a medication review
in each pharmacy. We used a random number generator in
excel 2010 for this selection. We expected that patients from
the highest tertile represented patients with a high complexity
and patients from the lowest percentile represented patients
with a low complexity. We selected five patients per complexity
degree and per pharmacy to comply with time constraints. The
pharmacists were instructed to perform an advanced medication
review as usual for patients with a high algorithm score and
were allowed to conduct any type of medication review for low
complexity patients based on their clinical judgment.
Agreement
The participating community pharmacists were asked to rate
case complexity of the selected patients on a 9-point Likert
scale (1 = low complexity, 9 = high complexity). The need
to perform a medication review for these patients was rated
on a separate 9-point Likert scale. Similarly, for each case
a pharmacist and a GP from the expert panels rated the
complexity of the case and the need for a medication review.
These ratings were averaged to provide one expert rating per
case. Kappa statistics were used to assess the agreement on
the complexity degree (high or low) between the algorithm
scores and the community pharmacists’ ratings. Similarly,
this was done for the agreement between the algorithm
scores and the experts’ ratings. Different cut-off points were
tested for the ratings on the 9-point scale, for which the
agreement and Kappa were calculated. The Kappa values were
interpreted as followed: <0.00 (poor), 0.00–0.20 (slight), 0.21–
0.40 (fair), 0.41–0.60 (moderate), 0.61–0.80 (substantial), and
0.81–1.00 almost perfect agreement (Fau and Koch, 1977).
Finally, we assessed agreement between the complexity degree
(high or low) indicated by the algorithm and the need for a
medication review indicated by the participating pharmacist and
the experts.
Pharmacists’ Views on the Feasibility
To assess feasibility, pharmacists were asked to share their
positive and negative views about the use of the new criteria as
compared to the current criteria (primary outcome). In-depth
interviews were held with the four participating pharmacists
by SC. These were face-to-face interviews using a topic list
which was developed to assess their views about the criteria
of the algorithm and applying them in practice (two domains
with eight topics) and explore the setting and procedures
regarding the conduct of medication reviews (two domains
with six topics). An overview of the topics can be found
in Appendix IV. The interviews were recorded, transcribed
and thematically coded by SC. A content analysis was
conducted to summarize information about the setting in
relation to the conducting of medication reviews. A deductive
approach was used to attain thematic codes related to the
participants’ positive and negative views about various criteria
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and the feasibility of applying such criteria in practice. The
data coding related to the setting was checked by KT and
thematic codes related to criteria and feasibility were checked
by PD.
Medication Review Evaluation
As process evaluation, we assessed the number of proposed
and implemented interventions as well as the time needed
for each step in the review of patients with high and low
complexity scores. The steps were preparation, anamnesis,
analysis, consultation with GP, and feedback to patient (van der
Meer et al., 2015). For each patient with a medication review a
structured case report form was completed by a pharmacist in
training together with the pharmacist containing the following
data: laboratory outcomes and morbidity from GP medical
records, background information obtained during anamnesis in
the pharmacy, the proposed and implemented interventions as
documented in the pharmacy medication record. Per review step
the pharmacist recorded the time involved. T-tests were used to
compare the time investment of the pharmacists and the number
of proposed and implemented interventions between patients
with high and low complexity scores.
RESULTS
The 59 cases provided by the experts combined with 21 additional
cases developed from these cases created a total of 80 cases, which
were rated by the experts on complexity. In the first Delphi round,
consensus was reached on 59 of the 80 cases, including 18 of the
additional cases. During the second round consensus was reached
on another 16 cases, including three additional cases. Consensus
was not obtained for five cases, which were excluded from further
analysis. The patient characteristics of the cases included in the
algorithm development are shown in Table 1.
Algorithm Development
A total of 14 potential criteria with a p-value of ≥0.25 in
the univariate testing were included in the first regression
model predicting the experts’ complexity rating (Appendix II).
An additional 10 alternative potential criteria were tested
during the stepwise procedure. In the final model, four
criteria remained which significantly predicted the complexity
rating (P < 0.0001) with an adjusted R2 of 0.73 (Table 2).
The regression model results were used to construct
the algorithm by multiplying the coefficients with 10.232
and rounding this to the nearest whole number. This
resulted in the algorithm with the following four criteria
and weighting:
′Number of different medications′ × 1 +
′Number of prescribers′ × 3 + ′Fall incident′ ×
7+ ′Does not collect own medication ′ × 4. This algorithm
has a minimum score of 8, since eligible patients have at least five
medications and one prescriber. The maximum algorithm score
is dependent on the number of medications and prescribers a
patient can have.
TABLE 1 | Patients characteristics of the 75 cases with expert panel consensus.
Variable Mean/% N Range
Age (years) 79 – 49–94
Weight (kg) 78 – 50–110
Male 48% 36 –
Number of medications 10 – 5–26
At least one unplanned hospitalization in
the last 12 months
24% 18 –
Number of prescribers 1.9 – 1–4
Does not collect his or her own medication
at the pharmacy
64% 47 –
Receives sachet packed medication 49% 35 –
QOF standard morbidity score (Carey
et al., 2013)
1.6 – 0–4
QOF extended morbidity score (excluding
renal disease) (Carey et al., 2013)
1.6 – 0–4
Mean complexity rating by expert panel 5.0 – 2–9
QOF, Quality and Outcomes Framework.
TABLE 2 | Case characteristics predicting complexity (final regression model).
Case characteristics Coefficient P-value
Number of different medications 0.232 <0.001
Number of prescribers 0.756 <0.001
At least one fall incident in the last 12 months
(1 = yes, 0 = no)
1.65 <0.001
Does collect his/her own medication at the




Of the 400 invited patients, 166 accepted to participate and
completed the questionnaire with information needed for
the algorithm. Forty patients were randomly selected for a
medication review, two of whom dropped out due to illness. Of
the remaining patients, 19 were from the lowest and 19 were
from the highest tertile of algorithm scores. General patient
characteristics of those two groups, such as age and sex, were
similar (Table 3).The pharmacists decided to conduct advanced
medication reviews for all 38 patients.
Agreement
Kappa values for agreement on complexity ratings ranged from
0.13 to 0.55 (Table 4). For the pharmacists’ ratings, the highest
agreement (Kappa of 0.42) was seen for the cut-off point of
≥7 (83.3% of the patients rated with a high complexity of 7
or more by the experts were equally scored by the algorithm).
For the experts’ ratings, the highest agreement (Kappa of
0.55) was seen for a lower cut-off point of ≥5 (74.3% of
the patients rated with a complexity of 5 or more by the
pharmacists were equally scored by the algorithm). Agreement
on the need for a review between the algorithm scores and
the community pharmacists’ or the experts’ ratings ranged
from 0.052 to 0.32 (Table 4). The highest observed Kappa was
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Total number (N) 19 19
Mean age (years) 74.5 76.7
Mean weight (kilogram) 86.4 82.5
Male (N) 11 12
Sachet packed medication (N) 1 4
At least one unplanned hospitalization in the
last 12 months (N)
1 6
Mean QOF standard morbidity score (Carey
et al., 2013)
0.4 1.1
Mean QOF extended morbidity score
(excluding renal disease) (Carey et al., 2013)
0.4 1.2
Mean number of medications 7.5 11.1
Mean number of prescribers 1.5 2.9
Does not collect own medication (N) 2 8
At least one fall incident in the last 12 months
(N)
0 6
Mean score algorithm 12.1 23.9
QOF, Quality and Outcomes Framework; N, number.
seen for cut-off point ≥8 for the pharmacists and ≥6 for
the experts.
Pharmacists’ Views on the Algorithm
From the interviews, the following five main themes were
identified: (1) views about the criteria included in the algorithm,
(2) criteria the pharmacists believed that could be relevant for
selection but were not included in the algorithm, (3) views
about the criteria as proposed by the Healthcare Inspectorate, (4)
feasibility of collecting the data needed to apply the algorithm, (5)
reliability of the data needed to apply the algorithm (Table 5).
Three pharmacists were supportive of including “the number
of medications” (Table 5, Q5) and two were supportive of “not
collecting their own medication” (Q2) as criteria for medication
reviews. One pharmacist saw “the number of prescribers” as
a relevant criterion. Using “fall incidents” as criterion elicited
mixed reactions with two pharmacists seeing this as important
(Q1, Q3) while two others saw “fall incidents” as less relevant
in clinical practice (Q4). Three pharmacists suggested “living
in a care home,” “diminished cognition,” “patients not included
in a healthcare program” (e.g., diabetes or cardiovascular
risk management) (Q6) and “patients avoiding healthcare” as
potential relevant criteria. Two pharmacists were critical of the
Healthcare Inspectorate’s current criteria. One observed that
the high age criterion would exclude younger patients with
polypharmacy, who may benefit from a medication review (Q7).
Another expressed a strong negative opinion saying that these
criteria were ridiculous, since almost no eligible patients can
be selected.
Mixed opinions were expressed as to the feasibility of
collecting data needed to apply the algorithm. Sending
questionnaires to all eligible patients was considered feasible by
two pharmacists (Q8) but judged as not worth the effort by one
TABLE 4 | Agreement of the algorithm score with the community pharmacists’





Agreement (%) Kappa (κ) Agreement (%) Kappa (κ)
COMPLEXITY RATING
≥4 63.1 0.26 73.7 0.47
≥5 68.4 0.37 77.6 0.55
≥6 68.4 0.37 73.7 0.47
≥7 71.1 0.42 61.8 0.24
≥8 57.9 0.16 56.6 0.13
NEED FOR MEDICATION REVIEW RATING
≥4 52.6 0.052 59.2 0.18
≥5 57.9 0.16 61.8 0.24
≥6 63.2 0.26 64.5 0.29
≥7 60.5 0.21 61.8 0.24
≥8 65.8 0.32 55.3 0.11
†
Kappa statistics were calculated for different cut-off points of the 9-point Likert scale,
e.g., for the complexity rating at a cut-off at ≥7 all patients rated 7 or higher were
categorized in the high complexity group and below 7 in the low complexity group; GP,
general practitioner.
of them (Q9), whilst a third pharmacist stated that the extra step
of collecting the required data would take too much time (Q12).
A fourth pharmacist preferred the use of criteria easily obtained
from the pharmacy information system (Q10). Collecting the
information on the recent fall incidents was considered most
difficult and time consuming. Three pharmacists mentioned that
asking patients could also lead to unreliable data (Q13, Q14).
Medication Review Evaluation
The total time involved for all the steps of the review was on
average 76.9min for patients with a high complexity score and
66.1min for patients with a low complexity score (Table 6). The
11min difference was not statistically significant (P = 0.134).
No difference was found in the number of interventions
resulting from the medication review. On average, 2.1
interventions (SD 1.2) were proposed for patients with high
scores and 2.3 interventions (SD 1.6) for patients with low scores
(P = 0.658). The number of implemented interventions did not
differ between patients with high and low complexity scores (1.6
+/− 1.3 vs. 1.6 +/− 1.2; P = 0.51). There was also no difference
in the type of proposed interventions (Table 7).
DISCUSSION
We developed an algorithm to select older people with
polypharmacy for different types of medication review based
on their case complexity. The algorithm used the following
criteria to calculate a score: number of different medications,
number of prescribers, collecting own medication, and having
had a severe fall in the last 12 months. It explained 73% of the
variation in complexity as rated by the experts. The agreement
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TABLE 5 | Themes with quotes from semi-structured interviews with the pharmacists (translated from Dutch).
Pharmacist number Quote number Theme with quotes
VIEWS ABOUT THE CRITERIA INCLUDED IN THE ALGORITHM
Ph1 Q1 Fall incidents are important of course. I thought at first there were a lot of things [criteria] missing, but when I
thought about it later it made sense.
Ph2 Q2 That can change over time [collects his/her own medication], but yes, I think that these are good criteria.
Ph3 Q3 Yes, they [criteria] seem good to me, especially fall incidents are something you have to be aware of in older
people. (…). I think the most important criteria are in there.
Ph4 Q4 Those fall criteria, I have had such people here. Did you fall? How often in the past year? Yes, I tripped once
because I did not see the curb or something. I find that difficult, what to do with that.
Ph4 Q5 Yes, number of medication; that is, of course, that makes it complex.
POSSIBLY RELEVANT CRITERIA NOT INCLUDED IN THE ALGORITHM
Ph2 Q6 What you see in medication reviews is that people are often already in disease programs (…) if people are not in
such programs, then you have somebody that you think, there is a lot to do.
VIEWS ABOUT CRITERIA AS PROPOSED BY THE HEALTHCARE INSPECTORATE
Ph3 Q7 I think the criteria of the Inspectorate are okay but on the other hand I rather have somebody who is young with a
lot of medication. Then I can do a lot, so that in the future they can use less (…) the older people may have a lower
kidney function but I find the younger are really more important.
FEASIBILITY OF COLLECTING THE DATA NEEDED FOR THE ALGORITHM
Ph1 Q8 If you can easily make a selection and list for sending letters, then I think it is feasible (…) The way it was done now
worked fine.
Ph2 Q9 Yes everything is possible but is it worth the effort? (…) Especially fall incidents, I think that would take the most
effort. That would require the most change.
Ph3 Q10 You would have to approach each patient to ask whether they have fallen recently and I think that would not be
something we would do soon. We would rather look for easier things (…) what we have on our computer.
Ph3 Q11 I think if you, for instance, would only exclude the fall incidents from your algorithm you would be able to
implement it a lot faster.
Ph4 Q12 We cannot document that. That is just not doable. (…) When patients have to wait for 3min they get impatient.
(…) So I think that is not feasible.
RELIABILITY OF THE DATA NEEDED FOR THE ALGORITHM
Ph2 Q13 I notice that people find such a question [about fall incidents in last 12 months] difficult to answer.
Ph4 Q14 For a lot of criteria, I wonder whether you get the correct information. Fall incidents, I wonder, number of
prescribers, I wonder. Number of medication, that is fairly evident.
TABLE 6 | Time the pharmacists needed to perform the medication reviews.
Step in review Low complexity High complexity P-value
Time (min) SD Time (min) SD
Preparation 11.2 5.5 12.2 6.6 0.616
Anamnesis 29.5 11.5 33.7 12.0 0.278
Analysis 14.5 6.9 18.9 7.2 0.057
Consultation with
GP
4.7 3.9 6.6 4.4 –
Feedback to
patient
6.3 5.7 5.5 4.4 –
Total time 66.1 20.8 76.9 22.4 0.134
Min, minutes; SD, standard deviation; GP, general practitioner.
between the participating pharmacists’ ratings and the algorithm
scores on complexity was slight to moderate. Pharmacists in
the pilot study had mixed opinions about the feasibility of
applying the algorithm in practice. The time needed to collect
the information for the criteria in the algorithm appeared to
be a major barrier. There was no significant difference in time
TABLE 7 | Number of proposed interventions in the low complexity and the high
complexity group.




De-intensification of medication 18 16
Intensification of medication 9 8
Requesting medical test results or therapeutic
drug monitoring
7 5
Intervention not otherwise specified 4 3
Substitution of medication 3 2
Watchful waiting 0 3
Medication administration instructions 2 1
Adherence counseling 0 2
Improving usability of medication 1 0
needed for a medication review between patients with high and
low complexity scores.
The number of prescribed medication, as included in our
algorithm, is often used as a selection criterion for medication
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reviews or other medication risk management interventions
(Huiskes et al., 2017). In the backward stepwise regression
procedure, we included other more sophisticated medication
scores but a simple count of the number of medications was
found to be the best predictor. This is in line with research
showing that theMedication Regimen Complexity Index (MRCI)
and the number of prescribed medications are equally predictive
for hospitalization (Wimmer et al., 2016). A clear benefit of using
a simple medication count compared to more complex scores
is that it can be calculated relatively easily from the pharmacy
information systems. Whether or not a patient collects his or her
own medication is a new and possibly meaningful criterion for
selecting patients. This criterion can be seen as a proxy for frailty
and vulnerability of the patient. We found that not collecting
his/her own medication was correlated with diminished mobility
and a smaller social network in the patients on which the
algorithm was based (data not shown). Furthermore, patients
who do not collect their own medication have less contact with
the pharmacy personnel. Reduced opportunities for pharmacy
personnel to communicate with the patient complicate patient
counseling and detecting medication problems. Fall risk has been
proposed before as criterion for conducting medication reviews
(Nederlands Huisartsen Genootschap, 2012). Severe falls in the
older population are recognized as an important cause of trauma
and hospitalizations (Gelbard et al., 2014). In part, these events
are medication-related (de Jong et al., 2013). However, evidence
is still limited that the withdrawal of high risk fall medication
as a singular intervention reduces the number of falls (Gillespie
et al., 2012; Boye et al., 2017). The number of prescribers has
not yet been used as criterion for medication reviews. It has been
shown, however, that patients with a larger number of prescribers
have a higher risk of inappropriate prescriptions (Hajjar et al.,
2005). Being under the care of multiple physicians possibly
indicates higher clinical complexity. Several criteria such as age
or kidney function, that are commonly used for selecting patients
for medication review (Huiskes et al., 2017), were not part of our
selection algorithm. The algorithm was developed for patients
of 65 years or older. Differentiating further on age within this
group did not contribute to predicting case complexity. This is in
line with research showing that in older populations the number
of potentially inappropriate medications is not associated with
age but rather with frailty (Wawruch et al., 2008; Ruggiero
et al., 2010; Poudel et al., 2014). Impaired kidney function has
often been associated with an increased risk of medication-
related hospitalizations and adverse drug reactions (Leendertse
et al., 2008; Onder et al., 2010; Sikdar et al., 2012). However, in
the Dutch setting this might be less relevant as criterion since
community pharmacists already monitor medication safety in
patients with a reduced kidney function (Koster et al., 2016).
The agreement between the algorithm scores on complexity
and the pharmacists’ ratings was at best moderate. In particular,
several patients with low complexity scores as calculated by the
algorithm were rated complex by the pharmacists. Agreement
was better regarding patients with high complexity, as indicated
by the higher Kappa value when using a cut-off score of 7
or more. This implies that the algorithm can be useful to
select the more complex patients for an advanced medication
review. Some of the remaining patients classified as simple
by the algorithm, however, may also be in need of an
advanced medication review based on clinical judgment of
the healthcare provider. Nonetheless, there were also patients
with low complexity scores that received similar low ratings
by the pharmacists. In the current system, they received an
advanced medication review but it is expected that such less
complex patients can receive a more simple and less time
consuming review. Reservations on the feasibility of applying
the algorithm in practice were primarily seen for collecting
information related to recent fall incidents. In contrast to the
other criteria, data on fall incidents cannot be acquired from
the pharmacy information system. However, eligible patients
could be asked by pharmacy staff about recent falls when
dispensing the medication. Implementation of pharmaceutical
care services in community pharmacies is often impeded by
a lack of time (van Mil et al., 2001; Kaae and Christensen,
2012). Hence, in order to successfully implement a criteria-based
algorithm the time investment should be minimized by making
the selection process automated where possible. Furthermore,
time invested in collecting data for the algorithm may be
compensated by performing shorter medication reviews for low
complexity patients.
All patients received advanced medication reviews regardless
of their complexity, possibly because only advanced reviews are
currently recommended and reimbursed in the Netherlands.
Consequently, differences in time investment for patients
with high or low algorithm scores were small and did
not reach statistical significance in our pilot study. Time
restrictions are among the most important barriers in
performing medication reviews (Niquille et al., 2010). A
time difference of more than 10min for low complexity patients
would allow a pharmacist to perform one additional review
for every six reviews performed in this group. Less time
consuming types of medication review, like a concordance or
prescription review, might be sufficient in certain low complexity
patients (Blenkinsopp et al., 2012).
Strengths and Limitations
A strength of our study is that we used the experts’ judgments
on case complexity to develop the criteria-based algorithm.
This allows for the identification of criteria that can be
proxies for criteria that may be difficult to acknowledge
or measure, and to search for the criteria that provide an
independent contribution. For instance, in the univariate analysis
an unplanned hospitalization in the last 12 months was a good
predictor for the complexity rating of the experts (Appendix II).
However, adding unplanned hospitalization to the regression
model failed to substantially improve the model. Thus, although
an unplanned hospitalization might have been considered a
relevant criterion from an expert’s point of view, it did not
provide additional information in combination with the other
criteria used in the model. Secondly, we used a Delphi method
with assessments on 9-point Likert scales, which allowed for
achieving a group statistical response, and included two expert
panels to increase the reliability of the consensus ratings. There
were several limitations to this study. Firstly, the algorithm was
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based on 80 cases of which 21 were modified. Since the modified
cases were fairly similar to the original cases, this might have
increased the weight that certain characteristics of these cases
had on the algorithm. On the other hand, by changing certain
characteristics we may have introduced more variety to these
characteristics. Although the characteristics that were varied were
not significant in the final model some bias in model building
cannot be excluded. Secondly, only patients with high and low
algorithm scores were invited for a medication review in the pilot
study. Patients in the intermediate group did not receive a review,
and no conclusions can be made about this group. Thirdly, out
of 400 patients invited, 166 were willing to participate, possibly
introducing a selection bias. This rate is similar in relation to
other Dutch studies in which advanced medication reviews are
conducted (Kwint et al., 2012; Willeboordse et al., 2017). Lastly,
the algorithm was applied in four community pharmacies in the
northern part of the Netherlands. To obtain more generalizable
results, a larger study is warranted.
Implications for Practice and Research
Although the algorithm performed well in predicting case
complexity as rated by the experts, the fair to moderate
performance for distinguishing between high and low complexity
patients in the pilot study indicates that it should only be used
as a screening tool for selecting complex patients for advanced
medication reviews. This pilot study is a first step toward a new
approach which allows for a more evidence-based differentiation
in the type of medication reviews conducted in practice. Given
the fact that our algorithm was developed using expert consensus
on a set of partlymodified cases, it needs to be validated in a larger
set of patients. This process may lead to adapting the algorithm
to improve its performance. Furthermore, optimal cut-off levels
for the degree of complexity in relation to the type of medication
review need to be confirmed. Finally, studies should be conducted
to assess the effects of this new approach on clinical outcomes.
In conclusion, we developed an algorithm with four criteria
that differentiates between high and low complexity patients
and allows allocation to simple or advanced medication reviews
accordingly. In practice, most feasibility problems were seen
regarding collection of information about recent falls. Additional
steps are needed to confirm the correctness of the four criteria.
Furthermore, steps are needed to facilitate data collection for
the algorithm, and to evaluate and improve the algorithm before
implementing it in practice.
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